UY29904A1 - Compuestos útiles en terapia - Google Patents

Compuestos útiles en terapia

Info

Publication number
UY29904A1
UY29904A1 UY29904A UY29904A UY29904A1 UY 29904 A1 UY29904 A1 UY 29904A1 UY 29904 A UY29904 A UY 29904A UY 29904 A UY29904 A UY 29904A UY 29904 A1 UY29904 A1 UY 29904A1
Authority
UY
Uruguay
Prior art keywords
therapy
alkyl
useful compounds
pelvic pain
chronic pelvic
Prior art date
Application number
UY29904A
Other languages
English (en)
Inventor
Sarah Elizabeth Skerratt
Kevin Neil Dack
Paul Anthony Bradley
Patrick Stephen Johnson
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of UY29904A1 publication Critical patent/UY29904A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de fórmula (I), o uno de sus derivados farmacéuticamente aceptables, en donde R1 y R3, H, R2, a, R4, R5, R7 y R8 representan, de modo independiente, H, alquilo C1-6,alquil C1-6oxi, CN o halógeno, o R4 y R5, R7 y R8, m, Y, y R6 son como se definieron en la memoria y reivindicaciones de utilidad para tratar endometriosis, fibroides uterino (leiomiomas), menorragia, adenomiosis, dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), o síndrome de dolor pélvico crónico.
UY29904A 2005-11-08 2006-11-08 Compuestos útiles en terapia UY29904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73509105P 2005-11-08 2005-11-08

Publications (1)

Publication Number Publication Date
UY29904A1 true UY29904A1 (es) 2007-06-29

Family

ID=37909834

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29904A UY29904A1 (es) 2005-11-08 2006-11-08 Compuestos útiles en terapia

Country Status (35)

Country Link
US (2) US7309712B2 (es)
EP (1) EP1948615B1 (es)
JP (1) JP4234786B1 (es)
KR (1) KR100997595B1 (es)
CN (1) CN101304974A (es)
AP (1) AP2008004463A0 (es)
AR (1) AR056780A1 (es)
AT (1) ATE537150T1 (es)
AU (1) AU2006313478A1 (es)
BR (1) BRPI0618630A2 (es)
CA (1) CA2628844C (es)
CR (1) CR9959A (es)
CY (1) CY1112286T1 (es)
DK (1) DK1948615T3 (es)
DO (1) DOP2006000245A (es)
EA (1) EA014693B1 (es)
EC (1) ECSP088431A (es)
ES (1) ES2376252T3 (es)
GT (1) GT200600478A (es)
HN (1) HN2006037713A (es)
IL (1) IL190806A0 (es)
MA (1) MA29940B1 (es)
NL (1) NL2000299C2 (es)
NO (1) NO20082504L (es)
PE (1) PE20070642A1 (es)
PL (1) PL1948615T3 (es)
PT (1) PT1948615E (es)
RS (1) RS20080191A (es)
SI (1) SI1948615T1 (es)
TN (1) TNSN08202A1 (es)
TW (1) TWI321563B (es)
UA (1) UA90763C2 (es)
UY (1) UY29904A1 (es)
WO (1) WO2007054770A2 (es)
ZA (1) ZA200803670B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
RS20080191A (en) * 2005-11-08 2009-07-15 Pfizer Limited, Pyrazole derivatives and their medical use
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2074084B1 (en) 2006-09-25 2013-08-28 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2008135824A1 (en) * 2007-05-02 2008-11-13 Pfizer Limited Oxyalkylpyrazole compounds useful in therapy
WO2009061652A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
WO2010036630A2 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節する化合物
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
TW202028195A (zh) * 2018-10-18 2020-08-01 大陸商南京聖和藥業股份有限公司 作為TGF-βR1抑制劑的化合物及其應用
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
CN111269097B (zh) * 2020-04-02 2023-02-17 苏州爱玛特生物科技有限公司 一种多元环双取代的1,3-丙二酮类化合物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281638A (ja) * 1985-10-07 1987-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS63313784A (ja) * 1987-03-12 1988-12-21 Zeria Shinyaku Kogyo Kk 新規ピラゾール誘導体およびその製造法ならびにこれを有効成分とする抗潰瘍剤
DE4414792A1 (de) * 1993-08-11 1995-02-16 Bayer Ag Arzneimittel enthaltend 1-Thiocarbamoyl-5-hydroxypyrazolen und deren Verwendung als Mittel zur Bekämpfung des septischen Schocks
AU2002242926B2 (en) * 2001-04-10 2007-10-11 Pfizer Inc. Pyrazole derivatives for treating HIV
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
RS20080191A (en) * 2005-11-08 2009-07-15 Pfizer Limited, Pyrazole derivatives and their medical use

Also Published As

Publication number Publication date
DOP2006000245A (es) 2007-06-30
UA90763C2 (ru) 2010-05-25
AR056780A1 (es) 2007-10-24
US20080085919A1 (en) 2008-04-10
AP2008004463A0 (en) 2008-06-30
JP4234786B1 (ja) 2009-03-04
MA29940B1 (fr) 2008-11-03
PT1948615E (pt) 2012-02-03
NL2000299C2 (nl) 2007-11-20
RS20080191A (en) 2009-07-15
BRPI0618630A2 (pt) 2011-09-06
EP1948615A2 (en) 2008-07-30
EA014693B1 (ru) 2010-12-30
GT200600478A (es) 2007-06-08
CA2628844C (en) 2011-12-06
CN101304974A (zh) 2008-11-12
TWI321563B (en) 2010-03-11
SI1948615T1 (sl) 2012-02-29
WO2007054770A2 (en) 2007-05-18
CY1112286T1 (el) 2015-12-09
ECSP088431A (es) 2008-06-30
TNSN08202A1 (fr) 2009-10-30
EP1948615B1 (en) 2011-12-14
CA2628844A1 (en) 2007-05-18
PE20070642A1 (es) 2007-08-24
DK1948615T3 (da) 2012-02-06
JP2009514938A (ja) 2009-04-09
EA200801053A1 (ru) 2008-10-30
CR9959A (es) 2008-08-01
TW200804295A (en) 2008-01-16
ATE537150T1 (de) 2011-12-15
IL190806A0 (en) 2008-11-03
NO20082504L (no) 2008-06-05
PL1948615T3 (pl) 2012-04-30
US7425569B2 (en) 2008-09-16
KR20080056761A (ko) 2008-06-23
NL2000299A1 (nl) 2007-05-09
US20070105909A1 (en) 2007-05-10
ZA200803670B (en) 2009-03-25
AU2006313478A1 (en) 2007-05-18
KR100997595B1 (ko) 2010-11-30
ES2376252T3 (es) 2012-03-12
HN2006037713A (es) 2010-06-09
WO2007054770A3 (en) 2007-10-04
US7309712B2 (en) 2007-12-18

Similar Documents

Publication Publication Date Title
UY29904A1 (es) Compuestos útiles en terapia
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
CY1121867T1 (el) Αναστολεις jak2 και alk2 και μεθοδοι για τη χρηση τους
AR053587A1 (es) Derivados de pirazol
NO20062032L (no) Derivater av N-[fenyl(pyrrolidin-2-yl)-metyl]benzamid og N-[(azepan-2-yl)fenylmetyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske midler
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
HRP20050682B1 (hr) Derivati pirazolopiridina
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
CY1108924T1 (el) Παραγωγα πυρρολιδινης και πιπεριδινης ως ανταγωνιστες νκ1
TW200619221A (en) Fused tricyclic derivatives
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
CU23550B7 (es) Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
ATE302775T1 (de) Carbolinderivate
CY1114112T1 (el) Νεα αρυλαμιδια υποκατεστημενα με πυραζολιο
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
NO20064706L (no) Thyroid reseptor agonister
ATE346067T1 (de) Carbolinderivate
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160920